Metizolam: Difference between revisions

Line 7:

|}</center>

~~'''~~'''Metizolam~~'''~~''' (also known as '''desmethyletizolam''') is a short-acting [[psychoactive]] drug of the [[thienodiazepine]] class that is closely related to [[etizolam]]. It has a 60% longer half life and 50% less potency than etizolam. It has been shown by annecdotal reports to produce [[depressant]], [[anxiolytic]], [[sedative]], [[hypnotic]], [[muscle relaxant]], [[anticonvulsant]], and [[amnestic]] effects.

'''Metizolam''' (also known as '''desmethyletizolam''') is a short-acting [[psychoactive]] drug of the [[thienodiazepine]] class that is closely related to [[etizolam]]. It has a 60% longer half life and 50% less potency than etizolam. It has been shown by annecdotal reports to produce [[depressant]], [[anxiolytic]], [[sedative]], [[hypnotic]], [[muscle relaxant]], [[anticonvulsant]], and [[amnestic]] effects.

This compound was patented by a japanese company in 1995 as an anti-anxiety medication<ref>Heteroaromaten mit anellierten Siebenringen, III. Umwandlung von Thienotriazolooxazepinen in Diazepine | https://dx.doi.org/10.1002%2Fjlac.197819780806</ref><ref>Triazolothienodiazepine compounds | http://www.google.com/patents/US3904641</ref><ref>Thienylazole compound and thienotriazolodiazepine compound | http://www.google.com/patents/EP0776892A1</ref> . Despite this however, it has little to no history of human usage prior to its release as a grey area research chemical by online vendors in September 2015.

@@ Line 7: / Line 7: @@
 |}</center>
 {{SubstanceBox/Metizolam}}
-''''''Metizolam'''''' (also known as '''desmethyletizolam''') is a short-acting [[psychoactive]] drug of the [[thienodiazepine]] class that is closely related to [[etizolam]]. It has a 60% longer half life and 50% less potency than etizolam. It has been shown by annecdotal reports to produce [[depressant]], [[anxiolytic]], [[sedative]], [[hypnotic]], [[muscle relaxant]], [[anticonvulsant]], and [[amnestic]] effects.
+'''Metizolam''' (also known as '''desmethyletizolam''') is a short-acting [[psychoactive]] drug of the [[thienodiazepine]] class that is closely related to [[etizolam]]. It has a 60% longer half life and 50% less potency than etizolam. It has been shown by annecdotal reports to produce [[depressant]], [[anxiolytic]], [[sedative]], [[hypnotic]], [[muscle relaxant]], [[anticonvulsant]], and [[amnestic]] effects.
 This compound was patented by a japanese company in 1995 as an anti-anxiety medication<ref>Heteroaromaten mit anellierten Siebenringen, III. Umwandlung von Thienotriazolooxazepinen in Diazepine | https://dx.doi.org/10.1002%2Fjlac.197819780806</ref><ref>Triazolothienodiazepine compounds | http://www.google.com/patents/US3904641</ref><ref>Thienylazole compound and thienotriazolodiazepine compound | http://www.google.com/patents/EP0776892A1</ref> . Despite this however, it has little to no history of human usage prior to its release as a grey area research chemical by online vendors in September 2015.